KDEV Stock Overview
A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Karolinska Development AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.22 |
| 52 Week High | SEK 1.95 |
| 52 Week Low | SEK 1.17 |
| Beta | 0.21 |
| 11 Month Change | -10.00% |
| 3 Month Change | -16.28% |
| 1 Year Change | -21.13% |
| 33 Year Change | -67.36% |
| 5 Year Change | -63.02% |
| Change since IPO | -96.94% |
Recent News & Updates
Recent updates
We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings
May 04
Is Karolinska Development (STO:KDEV) Using Too Much Debt?
Aug 19Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year
Apr 27We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings
Feb 08
Shareholder Returns
| KDEV | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -0.8% | -1.8% | 1.6% |
| 1Y | -21.1% | 67.6% | 21.0% |
Return vs Industry: KDEV underperformed the Swedish Pharmaceuticals industry which returned 69.3% over the past year.
Return vs Market: KDEV underperformed the Swedish Market which returned 20.6% over the past year.
Price Volatility
| KDEV volatility | |
|---|---|
| KDEV Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: KDEV's share price has been volatile over the past 3 months.
Volatility Over Time: KDEV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 8 | Viktor Drvota | www.karolinskadevelopment.com |
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.
Karolinska Development AB (publ) Fundamentals Summary
| KDEV fundamental statistics | |
|---|---|
| Market cap | SEK 330.28m |
| Earnings (TTM) | -SEK 5.65m |
| Revenue (TTM) | SEK 1.90m |
173.6x
P/S Ratio-58.5x
P/E RatioIs KDEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KDEV income statement (TTM) | |
|---|---|
| Revenue | SEK 1.90m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 1.90m |
| Other Expenses | SEK 7.55m |
| Earnings | -SEK 5.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 15, 2024
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 100.00% |
| Net Profit Margin | -296.85% |
| Debt/Equity Ratio | 0% |
How did KDEV perform over the long term?
See historical performance and comparison